Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Acerus Pharmaceuticals Corporation (ASPCF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.21990.0000 (0.00%)
At close: 09:53AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2199
Open0.2199
BidN/A x N/A
AskN/A x N/A
Day's Range0.2199 - 0.2199
52 Week Range0.0200 - 8.0000
Volume500
Avg. Volume83
Market Cap2.046M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ASPCF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ACERUS PHARMACEUTICALS CORP
    Analyst Report: Microsoft CorporationMicrosoft is the world's largest independent software developer. The company was founded on the MS Windows operating system and MS Office business applications suite for PCs. As it has grown, Microsoft has expanded into enterprise software with Windows Server, SQL Server, Dynamics CRM, SharePoint, Azure, and Lync; hardware with the Xbox gaming/media platform and the Surface tablet; and online services through MSN and Bing. Microsoft acquired Skype, the internet VoIP communications service, in October 2011. More than 50% of revenue is generated outside the U.S.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
Advertisement
Advertisement